In an early-stage breakthrough, scientists have developed a new family of compounds that could slow the progression of Parkinson’s disease. Parkinson’s is the second most common neurodegenerative disease and there is no treatment to slow the advance of the disease. The compounds are a new class of potential therapeutics.